Section ofEndocrinology 223 implantation itself has been infection in the tumour, which was usually a sequel of overt cerebrospinal fluid rhinorrhcea. Such a local infection can readily spread to give meningitis. Among the last 30 implants giving 50,000 rads (January 1968 to March 1969 there has been no instance of local infection, after the introduction of two important measures:
(1) Adequate pre-implant antiseptic treatment with chlorhexidine (Hibitane) (1/1,000) nasal spray, combined with antibiotic cover with cloxacillin for five days after implant.
(2) Starting trimethoprim (250 mg) and sulphamethoxazole (500 mg) twice daily immediately a cerebrospinal fluid leak is reported, and continuing this until the leak either heals spontaneously or is repaired.
Loss of anterior pituitary function to the extent that cortisone or thyroxine became necessary occurred after 28 % of implants (Table 2) or in 20% if we exclude those deliberately given total ablation doses. Loss of ACTH or TSH was not necessarily combined with loss of GH secretion. Among 15 patients attaining normal GH levels, 11 also lost other anterior pituitary function; among the 18 hypopituitary patients needing thyroxine and cortisone, there were 7 who still had abnormally high-GH levels (Fig 3) .
Diabetes insipidus occurred after 16 implants (17%), but in only 4 has permanent vasopressin treatment been required. Hyponatremia due to 'inappropriate' ADH was observed after one of the implants.
Conclusions
(1) A satisfactory clinical response was achieved by yttrium implantation in more than half of 80 acromegalic patients. Hypopituitarism occurred in a quarter. Cerebrospinal fluid rhinorrhea occurred in 13 % and local infection in 12%.
(2) Considerable improvement in the visual field defects was observed in all 5 patients so affected.
(3) The changes observed in serum GH levels did not always mirror the clinical response; a satisfactory clinical response appeared to need both a pronounced percentage fall as well as a fall to below an absolute level between 10-50 ng/ml. Plasma Growth Hormone in the Long-term Follow Up of X-ray-treated and Untreated Acromegalics The growth hormone (HGH) levels of 42 untreated acromegalic patients were measured by the radioimmunoassay of Hunter & Greenwood (1964) . The test procedure consisted of 6-8 samples taken at half-hourly intervals with oral glucose, 50 g, being given immediately after the third sample. Tests conducted on different occasions within a period of six months on the same patients gave mean HGH values which were within or just outside the overlap of their SEMs.I The range for untreated acromegalics was 5-500 ng HGH/ml plasma, values being expressed in terms of MRC HGH Standard A. Ten patients were reassessed by HGH assay before and at intervals after X-ray therapy (3,500 rads). HGH levels did not change during the first 6 months after this treatment. During the next 18 months HGH levels either remained unchanged (3 cases), fell (5 cases) or increased (2 cases).
[A full report will appear elsewhere.] REFERENCE Hunter W M& Greenwood F C (1964) Biochem. J. 19, 43 'Since this paper was read two errors have become apparent. Of the 5 cases of untreated acromegaly reported at that time, one was subsequently found to have received cryosurgical treatment.
Repeated determinations of HGH on another case which was reported as showing a marked spontaneous fall in fact showed no change and we must conclude that our previous results were due to a technical error. The conclusion that spontaneous major changes in plasma HGH levels may occur frequently in untreated acromegalics cannot now be supported by our data. 
